UnknownEarly Phase 1

Three Induction Treatments on Cryptococcal Meningitis

China120 participantsStarted 2021-01-25

Plain-language summary

Three induction treatment strategies \[ voriconazole +5FC vs. amphotericin deoxycholate (0.4-0.5 mg/kg/d)+5FC vs. amphotericin deoxycholate (0.7-1.0 mg/kg/d)+5FC \] for HIV-infected patients with cryptococcal meningitis were compared.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Clinical diagnosis of HIV infection;
✓. newly diagnosed Cryptococcal Meningitis by positive India ink staining or culture result, or both in cerebrospinal fluid (CSF);
✓. Anti-viral treatment naïve patients
✓. anti-fungal treatment naïve patients

Exclusion criteria

✕. hepatitis virus co-infection;
✕. liver cirrhosis;
✕. congestive heart failure;
✕. chronic renal disorders;
✕. chronic obstructive pulmonary disease (COPD);
✕. Tuberculosis co-infection;
✕. malignances
✕. severe mental and neurological diseases

What they're measuring

90-day Cryptococcal Meningitis (CM) related mortality

Timeframe: 90 days

Trial details

NCT IDNCT04072640

SponsorFirst Affiliated Hospital of Zhejiang University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-07-31

View on ClinicalTrials.gov More Cryptococcal Meningitis trials